Info: Read More
  • 中药标准品生产商,产品定制服务
  • Science | Nature | Cell | View More



    产品编号 CFN98174
    CAS编号 31008-19-2
    分子式 = 分子量 C21H22O6 = 370.39
    产品纯度 >=98%
    物理属性 Cryst.
    化合物类型 Lignans
    植物来源 The flowers of Magnolia biondii Pamp.
    产品名称 产品编号 CAS编号 包装 QQ客服
    辛夷脂素 CFN98174 31008-19-2 10mg QQ客服:3257982914
    辛夷脂素 CFN98174 31008-19-2 20mg QQ客服:3257982914
    辛夷脂素 CFN98174 31008-19-2 50mg QQ客服:3257982914
    辛夷脂素 CFN98174 31008-19-2 100mg QQ客服:3257982914
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: 或

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.

    PMID: 30417089
  • University of Fribourg (Switzerland)
  • Chungnam National University (Korea)
  • Mendel University in Brno (Czech Republic)
  • National Cancer Institute (USA)
  • Deutsches Krebsforschungszentrum (Germany)
  • University of Madras (India)
  • Seoul National University (Korea)
  • Aarhus University (Denmark)
  • Universidad de Ciencias y Artes de Chiapas (Mexico)
  • University of South Australia (Australia)
  • Monash University (Australia)
  • Max-Planck-Insitut (Germany)
  • Washington State University (USA)
  • Universidade Federal de Pernambuco (UFPE) (Brazil)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Acta Chromatographica2016, 29(3)
  • Semyung University2017, 149407
  • Biochem Biophys Res Commun.2017, 482(4):1095-1101
  • PLoS One.2018, 13(4):e0195642
  • Microchemical Journal2018, 137:168-173
  • Bioorg Med Chem.2018, 26(14):4201-4208
  • Sci Rep.2018, 8(1)
  • J Chromatogr B Analyt Technol Biomed Life Sci.2019, 1113:1-13
  • J Pharm Biomed Anal.2019, 172:268-277
  • Exp Ther Med.2019, 18(6):4388-4396
  • BMC Complement Altern Med.2019, 19(1):339
  • Molecules.2019, 24(22):E4022
  • Academic J of Second Military Medical University2019, 40(1)
  • J Sep Sci.2019, 42(21):3352-3362
  • J Asian Nat Prod Res.2019, 5:1-17
  • Drug Des Devel Ther.2020, 14:61-71
  • Nutrients.2020, 12(3):595.
  • Biomed Pharmacother.2020, 125:109784.
  • J Vet Sci.2020, 21(3):e39.
  • Molecules.2020, 25(15):3353.
  • Biochem Biophys Res Commun.2020, 530(1):4-9.
  • Clin Exp Pharmacol Physiol.2020, doi: 10.1111
  • Research Square2020, doi: 10.21203.
  • ...
  • 生物活性
    Description: Fargesin has anti-inflammatory, anti-cancer, antihypertensive , and anti-bone-resorbing effects, it is widely used in the treatment of managing rhinitis, inflammation, histamine, sinusitis, and headache. Fargesin improves lipid and glucose metabolism in 3T3-L1 adipocytes and high-fat diet-induced obese mice by activating Akt and AMPK in WAT. It as a potential β1 adrenergic receptor antagonist protects the hearts against ischemia/reperfusion injury in rats via attenuating oxidative stress and apoptosis.
    Targets: Akt | AMPK | GLUT | PI3K | COX | SOD | cAMP | PKA | Caspase | PPAR | TNF-α | AP-1 | NF-kB | NOS | JNK | IL Receptor | PKC | MAPK | NO | TGF-β/Smad
    In vitro:
    Fitoterapia. 2015 May 27;105:16-25.
    Fargesin as a potential β1 adrenergic receptor antagonist protects the hearts against ischemia/reperfusion injury in rats via attenuating oxidative stress and apoptosis.[Pubmed: 26025856]
    Fargesin displayed similar chromatographic retention peak to metoprolol in the cardiac muscle/cell membrane chromatography (CM/CMC) and β1 adrenergic receptor/cell membrane chromatography (β1AR/CMC) models.
    To provide more biological information about fargesin, we investigated the effects of fargesin on isoproterenol-(ISO-) induced cells injury in the high expression β1 adrenergic receptor/Chinese hamster ovary-S (β1AR/CHO-S) cells and occluding the left coronary artery- (LAD-) induced myocardial ischemia/reperfusion (MI/R) injury in rats. The results in vitro showed that ISO-induced canonical cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) levels were decreased by fargesin in β1AR/CHO-S cells. Fargesin attenuated the serum creatine kinase (CK), lactate dehydrogenase (LDH), and improved histopathological changes of ischemic myocardium compared with the I/R rats. Similar results were obtained with Evans Blue/TTC staining, in which fargesin notably reduced infarct size. Moreover, compared with the I/R group, fargesin increased COX release and the activities of some endogenous antioxidative enzymes including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), but suppressed malondialdehyde (MDA), and intracellular ROS release. Additionally, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay demonstrated fargesin suppressed myocardial apoptosis, which may be related to inhibition of caspase-3 activity.
    Taken together, these results provided substantial evidences that fargesin as a potential β1AR antagonist through cAMP/PKA pathway could protect against myocardial ischemia/reperfusion injury in rats. The underlining mechanism may be related to inhibiting oxidative stress and myocardial apoptosis.
    Phytomedicine. 2017 Jan 15;24:96-103.
    Fargesin exerts anti-inflammatory effects in THP-1 monocytes by suppressing PKC-dependent AP-1 and NF-ĸB signaling.[Pubmed: 28160867 ]
    Fargesin is a lignan from Magnolia fargesii, an oriental medicine used in the treatment of nasal congestion and sinusitis. The anti-inflammatory properties of this compound have not been fully elucidated yet. This study focused on assessing the anti-inflammatory effects of fargesin on phorbal ester (PMA)-stimulated THP-1 human monocytes, and the molecular mechanisms underlying them.
    Cell viability was evaluated by MTS assay. Protein expression levels of inflammatory mediators were analyzed by Western blotting, ELISA, Immunofluorescence assay. mRNA levels were measured by Real-time PCR. Promoter activities were elucidated by Luciferase assay. It was found that pre-treatment with fargesin attenuated significantly the expression of two major inflammatory mediators, cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). Fargesin also inhibited the production of pro-inflammation cytokines (IL-1β, TNF-α) and chemokine (CCL-5). Besides, nuclear translocation of transcription factors nuclear factor-kappa B (NF-ĸB) and activator protein-1 (AP-1), which regulate multiple pro-inflammatory genes, was suppressed by fargesin in a PKC-dependent manner. Furthermore, among the mitogen-activated protein kinases (MAPKs), only c-Jun N-terminal kinase (JNK) was downregulated by fargesin in a PKC-dependent manner, and this reduction was involved in PMA-induced AP-1 and NF-ĸB nuclear translocation attenuation, demonstrated using a specific JNK inhibitor.
    Taken together, our results found that fargesin exhibits anti-inflammation effects on THP-1 cells via suppression of PKC pathway including downstream JNK, nuclear factors AP-1 and NF-ĸB. These results suggest that fargesin has anti-inflammatory properties with potential applications in drug development against inflammatory disorders.
    Invest New Drugs. 2014 Feb;32(1):1-13.
    Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.[Pubmed: 23673814]
    Breast cancer frequently spreads to bone. The interaction between bone metastases and microenvironment, referred as the "vicious cycle", increases both tumor burden and bone destruction. Therefore, inhibition at any point in this "vicious cycle" can reduce malignant osteolytic lesions in patients with advanced breast cancer.
    In this study, we evaluated whether tetrahydrofurofuran-type lignans derived from Magnoliae Flos, commonly used in traditional Asian medicine to treat inflammatory diseases, could block breast cancer-mediated bone loss. Aschatin, fargesin, lirioresinol B dimethyl ether, and magnolin at noncytotoxic concentrations suppressed mRNA expression and secretion of osteolytic factor PTHrP in MDA-MB-231 metastatic human breast cancer cells. Fargesin inhibited TGF-β-stimulated cell viability, migration, and invasion and decreased TGF-β-induced PTHrP production in MDA-MB-231 cells. In addition, these lignans reduced RANKL/OPG ratio in PTHrP-treated hFOB1.19 human osteoblastic cells and inhibited RANKL-mediated osteoclast differentiation in mouse bone marrow macrophages. Aschatin, fargesin, lirioresinol B dimethyl ether, and magnolin substantially reduced bone-resorbing activity of osteoclasts by inhibiting MMP-9 and cathepsin K activities. Furthermore, orally administered fargesin inhibited tumor growth and cancer-mediated bone destruction in mice with MDA-MB-231 cells injected into calvarial tissues. Aschatin, fargesin, lirioresinol B dimethyl ether, and magnolin blocked initiation and progression of the "vicious cycle" between breast cancer metastases and bone microenvironment by inhibiting PTHrP production in breast cancer cells and osteoclastic bone resorption.
    Therefore, these tetrahydrofurofuran-type lignans have the potential to serve as beneficial agents to prevent and treat cancer-induced bone destruction in breast cancer patients.
    In vivo:
    Can J Physiol Pharmacol. 2016 Aug;94(8):900-6.
    Antihypertensive effects of fargesin in vitro and in vivo via attenuating oxidative stress and promoting nitric oxide release.[Pubmed: 27409158 ]
    Fargesin, a bioactive neolignan isolated from magnolia plants, is widely used in the treatment of managing rhinitis, inflammation, histamine, sinusitis, and headache. To provide more biological information about fargesin, we investigated the effects of fargesin on rat aortic rings and 2-kidney, 1-clip (2K1C) hypertensive rats.
    In vitro, fargesin caused concentration-dependent vasorelaxation in rat isolated aortic rings induced by KCl and norepinephrine. The effect was weakened by endothelium denudation and nitric oxide (NO) synthesis inhibition. In vivo, the evolution of systolic blood pressure (SBP) was followed by weekly measurements. Angiotensin II (Ang II) and endothelin (ET) levels, NO and nitric oxide synthase (NOS), and plasma and liver oxidative stress markers were determined at the end of the experimental period. After 5 weeks of fargesin treatment, we found that fargesin treatment reduced SBP, cardiac hypertrophy, and Ang II and ET levels of hypertensive rats. Increased NOS activity and NO level were observed in fargesin-treated rats. Normalisation of plasma MDA concentrations and improvement of the antioxidant defence system in plasma and liver accompanied the antihypertensive effect of fargesin.
    Taken together, these results provided substantial evidences that fargesin has antihypertensive effect in 2K1C hypertensive rats via inhibiting oxidative stress and promoting NO release.
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.6999 mL 13.4993 mL 26.9986 mL 53.9971 mL 67.4964 mL
    5 mM 0.54 mL 2.6999 mL 5.3997 mL 10.7994 mL 13.4993 mL
    10 mM 0.27 mL 1.3499 mL 2.6999 mL 5.3997 mL 6.7496 mL
    50 mM 0.054 mL 0.27 mL 0.54 mL 1.0799 mL 1.3499 mL
    100 mM 0.027 mL 0.135 mL 0.27 mL 0.54 mL 0.675 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    (-)-丁香树脂酚-4-O-beta-D-呋喃芹糖基-(1→2)-beta-D-吡喃葡萄糖苷; (-)-Syringaresinol 4-(2''-apiosylglucoside) CFN99504 136997-64-3 C33H44O17 = 712.69 10mg QQ客服:2932563308
    (+)-表松脂酚; (+)-Epipinoresinol CFN92288 24404-50-0 C20H22O6 = 358.4 5mg QQ客服:2159513211
    Kobusin; Kobusin CFN89280 36150-23-9 C21H22O6 = 370.40 10mg QQ客服:2056216494
    (-)-细辛脂素; (-)-Asarinin CFN90144 133-04-0 C20H18O6 = 354.35 20mg QQ客服:2159513211
    (-)-表松脂酚; (-)-Epipinoresinol CFN92420 10061-38-8 C20H22O6 = 358.4 5mg QQ客服:3257982914
    连翘脂素; Phillygenin CFN90511 487-39-8 C21H24O6 = 372.41 20mg QQ客服:2056216494
    连翘苷; Phillyrin CFN99998 487-41-2 C27H34O11 = 534.56 20mg QQ客服:3257982914
    辛夷脂素; Fargesin CFN98174 31008-19-2 C21H22O6 = 370.39 20mg QQ客服:1413575084
    细辛脂素; Asarinin CFN90628 133-05-1 C20H18O6 = 354.35 20mg QQ客服:3257982914
    刺五加苷D; Eleutheroside D CFN98510 79484-75-6 C34H46O18 = 742.72 10mg QQ客服:2056216494





    在线QQ1: 2056216494 ; QQ2: 3257982914


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产